IHC and germline testing are available for add-on ordering. Talk to a Guardant Health representative to learn more.
Novel clinical insights powered by
| Category | Description | Feature | Intended Use |
|---|---|---|---|
MOLECULAR
TUMOR TYPE |
Utilize epigenomic signatures to provide insight into tumor type
|
Molecular
tumor typing |
Utilize epigenomic signatures to help identify tissue of origin2
|
THERAPY
RESPONSE INSIGHT |
Provide insight into how patients might respond to a certain therapy
|
HRD
|
Determine HRD status in breast, pancreatic, and ovarian cancers to help inform the use of PARP inhibitor and platinum-based chemotherapies3
|
|
HLA genotyping
|
Use HLA typing as a biomarker to help inform therapy selection and clinical trial enrollment4,5
|
||
ENHANCED
PATIENT IDENTIFICATION |
Provide additional information to identify patients who might be eligible for a targeted therapy
|
Pharmacogenomics
|
Optimize treatment and reduce toxicity by identifying alleles in CYP2D6, DPYD, UGT1A1, HLA-B, and TPMT6
|
|
Viral status*
|
Detect EBV and HPV to assess prognosis, predict response, and distinguish cancer type7,8
|
The most advanced multiomic tissue test delivering DNA, RNA, and epigenomic insights.1*†
*Guardant360 Liquid analyzes 741 DNA genes and fusions in 367 RNA genes, plus TMB, MSI status, and methylation-based features. RNA is automatically included, but providers can opt out via the Test Requisition Form.
†Compared to other leading comprehensive tissue tests. The “most advanced” referring to the first and only commercially available tissue test to deliver multiomic insights from a single input.
IHC, immunohistochemistry;MSI, microsatellite instability;
PD-L1, programmed death-ligand 1; TMB, tumor mutation burden.
Important note: Guardant360 Tissue was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been reviewed or approved by the US FDA.
Home Screening MRD + Monitoring Treatment Selection